OTLK Q1 EPS Estimate Lowered by Brookline Capital Management

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Brookline Capital Management reduced their Q1 2025 earnings estimates for shares of Outlook Therapeutics in a research report issued to clients and investors on Monday, December 30th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of ($0.70) per share for the quarter, down from their previous forecast of ($0.62). The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($3.84) per share. Brookline Capital Management also issued estimates for Outlook Therapeutics’ Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($2.00) EPS and FY2027 earnings at $1.26 EPS.

OTLK has been the topic of a number of other research reports. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, November 29th. Ascendiant Capital Markets dropped their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Finally, BTIG Research decreased their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Outlook Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $32.73.

Outlook Therapeutics Stock Up 1.6 %

Shares of Outlook Therapeutics stock opened at $1.89 on Wednesday. The firm has a market cap of $44.71 million, a PE ratio of -0.18 and a beta of 0.46. Outlook Therapeutics has a 52 week low of $0.87 and a 52 week high of $12.85. The business’s fifty day simple moving average is $3.66 and its 200-day simple moving average is $5.79.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06.

Institutional Trading of Outlook Therapeutics

Several hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new position in Outlook Therapeutics in the second quarter worth approximately $75,000. Christensen King & Associates Investment Services Inc. acquired a new stake in shares of Outlook Therapeutics in the 3rd quarter valued at $55,000. Barclays PLC lifted its position in shares of Outlook Therapeutics by 677.4% during the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock worth $111,000 after purchasing an additional 18,249 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Outlook Therapeutics by 55.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock worth $275,000 after purchasing an additional 18,287 shares in the last quarter. Finally, State Street Corp increased its holdings in Outlook Therapeutics by 10.0% in the third quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after buying an additional 21,201 shares during the last quarter. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.